{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028157","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.478885+00:00","generated_at":"2026-05-31T20:18:31.113274+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Provectus announces up to $10M convertible loan financing at 8% interest","bullets":["Board approved term sheet for up to $10M unsecured convertible loan (2024 Financing) from multiple investors.","Loan bears 8% annual interest, matures in 12 months, convertible into Series D-1 Preferred at $2.8620/share.","Series D-1 Preferred convertible into 10 shares of common stock per preferred share.","Proceeds will fund drug discovery and development programs and G&A expenses.","Also closed previously reported 2022 Financing totaling $4,865,500 as of July 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028157","json":"https://secwatch.observer/filing/0001493152-24-028157.json","markdown":"https://secwatch.observer/filing/0001493152-24-028157.md","text":"https://secwatch.observer/filing/0001493152-24-028157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/0001493152-24-028157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224028157/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:18:31.113274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}